graduate at Farmácia from Universidade Federal Fluminense (1981), master's at Farmacos e Medicamento from Universidade de São Paulo (1987) and ph.d. at Biochemistry from Universidade de São Paulo (1995). Has experience in Pharmacy, focusing on Pharmacotechnie, acting on the following subjects: praziquantel, lipossomas, nanotecnologia, fosfatidilcolina and liposomes. (Source: Lattes Curriculum)
| News published in Agência FAPESP Newsletter about the researcher |
| TITULO |
| Articles published in other media outlets (0 total): |
| More itemsLess items |
| VEICULO: TITULO (DATA) |
| VEICULO: TITULO (DATA) |
Nanostructured systems with mucoadhesive properties have great potential to be employed in drug release. These systems may increase the residence time of the systems at the site of action or absorption, enhancing drug contact with the mucosal epithelial barrier. The increased of the residence time and of the accumulation of drugs at pathological sites associated with drug controlled rele…
Colorectal cancer (CC) ranks the third among the most common worldwide, which reinforces the urgent need for more effective or alternative treatments. A special emphasis regarding treatment modalities should consider drugs that can act against the angiogenesis process, which is directly related to tumor development. Based on nanotechnology tools, the development of polymeric nanoparticles…
Colorectal Cancer is a public health problem, among types of Cancer occupy the third position in terms of incidence and the second in mortality. For years, intravenous chemotherapy has been the therapeutic resource used in the treatment of Cancer, however, limited therapeutic efficacy and adverse effects compromise the use by this route. Bevacizumab (BVZ) was the first FDA approved (Food …
Prostate cancer is the most incident neoplasm in men in the world. This neoplasm affects approximately 32% of the male population. Among the chemotherapeutics recently employed in therapy, we highlight the abiraterone, which acts in inhibition of the enzyme CYP17 (responsible for the synthesis of androgens). Abiraterone was approved by the Food and Drug Administration (FDA) in 2012 for us…
Chron's disease (CD) is a type of inflammatory bowel disease (IBD) characterized by transmural inflammation, which affects the entire thickness of the organ. The mucosa, submucosa and muscular layer of discontinuous parts of the GIT are affected by the inflammatory process and the presence of ulcerations. Recent studies point to mucosal healing as the guiding paradigm for CD therapy. Here…
Prostate cancer is one of the neoplasms that most affects the male population in Brazil and worldwide, which classifies it a serious public health problem. Abiraterone stands out among the most promising antineoplastics drugs due to its efficacy and control of adverse effects compared to other agents. However, despite numerous clinical advantages, abiraterone, like other chemotherapeutic …
Ulcerative colitis (UC) is characterized by intense mucosal inflammation accompanied by ulceration, edema and hemorrhage. The most recent studies point to a new paradigm for the treatment of the disease, mucosal healing. The search for new approaches in the treatment of UC has defined mucus as an important biological target to consider, as it is related to the mucosal healing process. Rec…
(Only some records are available in English at this moment)
Colorectal cancer (CRC) affects thousands of people, being the third most prevalent in the world. Bevacizumab (BVZ) drug, already consolidated for other cancer treatments, exhibits limitations to oral administration because of it's proteic structure. In this way, the use of nanotechnology may help to search for new alternatives that are capable to improve BVZ biopharmaceutical characteri…
Colorectal cancer (CRC) is the third most common type of cancer in terms of incidence and the second most lethal in the world. Intravenous chemotherapy has been the therapeutic resource used in the treatment of cancer, however, the therapeutic effectiveness and the adverse effects are limited. compromise their use in this way. The colon-specific release of bevacizumab (BVZ) from nanostruc…
Glioblastomas (GBM) account 77% of malignant tumors that occurs on central nervous system (SNC) and today, despite all advances in chemotherapy, radiotherapy and neurosurgery, remains with limited prognosis. The existence of physiological barriers, especially blood brain barrier (BBB), represents the main obstacle that limits adequate concentrations of the drugs designed to therapy. Due t…
(Only some records are available in English at this moment)
| 4 / 2 | Completed research grants |
| 3 / 3 | Ongoing scholarships in Brazil |
| 26 / 18 | Completed scholarships in Brazil |
| 9 / 9 | Completed scholarships abroad |
| 42 / 32 | All research grants and scholarships |
| Associated processes | |
CV Lattes
ORCID